News
EDIT
5.49
-1.08%
-0.06
Editas Medicine To Present Pre-Clinical Data Demonstrating Progression Of In Vivo Medicines Pipeline At American Society Of Gene And Cell Therapy Annual Meeting
Editas Medicine presentations at ASGCT include oral presentation of in vivo pre-clinical data from mouse studies. Research on identifying potent large serine recombinases as a foundation to develop novel in vivo gene editing technologies for developing medicines. The company is developing an in-vivo gene editing technology.
Benzinga · 10h ago
Weekly Report: what happened at EDIT last week (0415-0419)?
Weekly Report · 21h ago
Weekly Report: what happened at EDIT last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at EDIT last week (0401-0405)?
Weekly Report · 04/08 09:12
Shareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week
Share price of Editas Medicine, Inc. Has dropped 26% in the last three months. The company's share price has declined 83% in three years. In the same period of time the company's revenue has shrunk by 34% per year. The firm is not profitable, and has lost 12% of its value over the last five years. We look at the fundamentals of the company to see if the stock is worth buying.
Simply Wall St · 04/06 12:19
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at EDIT last week (0325-0329)?
Weekly Report · 04/01 09:12
Biotech Roundtable: Is CRISPR all its cracked up to be?
CRISPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. The FDA approved the first CRISPR product for the US market last fall. Is CRisPR overhyped? Which companies are most attractive right now in the space? Seeking Alpha biotech analysts Stephen Ayers and Edmund Ingham weigh in.
Seeking Alpha · 03/26 15:43
Weekly Report: what happened at EDIT last week (0318-0322)?
Weekly Report · 03/25 09:12
Weekly Report: what happened at EDIT last week (0311-0315)?
Weekly Report · 03/18 09:12
XBI's Holdings Could Mean 52% Gain Potential
NASDAQ · 03/15 10:43
Weekly Report: what happened at EDIT last week (0304-0308)?
Weekly Report · 03/11 09:11
Editas Medicine President Gilmore O’Neill Sells 45% Of Holding
Gilmore O’Neill, the President of Editas Medicine, Inc. Recently sold shares at an average price of US$9.42. It was the biggest sale by an insider in the last 12 months. In the last year Editas medicine insiders didn't buy any company stock. The insider sale of shares is not a good sign for shareholders of the company. But the company does have a low level of insider ownership.  Editas Medicine insiders own about 0.3% of the shares in the firm.
Simply Wall St · 03/10 12:19
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Editas Medicine's share price has rebounded 28% in the last 30 days. The company's price-to-sales ratio of 9.3x still lags most other companies in the biotech industry. Its revenue growth has been superior to most others, but the company's three-year growth rate has been disappointing. Editas Medicine has a low price to sales ratio but its share price is still lagging the industry.
Simply Wall St · 03/09 12:02
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
Editas Medicine is developing a gene therapy to treat rare blood disorders sickle cell disease and beta thalassemia. The FDA is now on board with the company's proposal to run its lead program as a combined clinical trial. Citigroup analyst is calling for Editas Medicine's stock to rise from $10 to $16.
The Motley Fool · 03/07 08:31
Editas Medicine (EDIT) Receives a New Rating from a Top Analyst
TipRanks · 03/05 12:25
1 Beaten-Down Stock With 55% Upside, According to Wall Street
Editas Medicine is a clinical-stage gene editing-focused biotech company. The company has reported encouraging data from an ongoing trial for a potential medicine for two rare blood disorders. Editas Medicine's average price target of $15.64 implies an upside of 55% over its stock price. Can the company meet Wall Street's target in the next year?
The Motley Fool · 03/04 15:30
Weekly Report: what happened at EDIT last week (0226-0301)?
Weekly Report · 03/04 09:12
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Shares of Editas Medicine soared as much as 41.6% this week. The company's fourth-quarter results were better than expected. The gene editing specialist's stock is now up 34.8%. Editas also announced it is aligned with the FDA. But the company has just one clinical-stage program.
The Motley Fool · 03/03 02:49
More
Webull provides a variety of real-time EDIT stock news. You can receive the latest news about Editas Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).